An interventional study of Simple electrolysis percutaneous and Multifiliar Electrolysis percutaneus in Tendinopathy, sponsored by Universidad Pontificia de Salamanca. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Universidad Pontificia de Salamanca · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Tendinopathy with a site in Spain — 9 open to participants now, 9 under way, none of them phase 3. Tendinopathy · Spain.
Among the 42 studies in Tendinopathy with a site in Spain, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 with no phase, and was the 41st registered.
399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →9 of the 42 studies in Tendinopathy with a site in Spain are open now. Recruiting first, the newest first:
ReSport Clinic · Sites in Spain
Ages 18+
Universidad de Zaragoza · Sites in Spain
Ages 18+
Universidad Pontificia de Salamanca · Sites in Spain
Ages 18–65
University of Valencia · Sites in Spain
Ages 18–50 · Healthy volunteers
University of Cadiz · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 6 started in 2026.
This study's enrollment of 90 is above the median of 48 across 333 interventional studies indexed under Tendinopathy.
Median enrollment 60 across the 39 interventional studies, 100 across the 3 observational. Of the 26 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 42 have an industry lead sponsor. The 10 most frequent:
Universidad Pontificia de Salamanca is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Universidad Pontificia de Salamanca has 3 studies filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
2 of the studies in Tendinopathy with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07929675DAVID CRUZ DÍAZUltrasound-Guided Percutaneous Electrolysis Plus Exercise for Chronic Supraspinatus Tendinopathy | 2027-03-01 |
| NCT06729437University of ValenciaTranscranial Direct Current Stimulation on Functionality and Pain in Individuals With Patellar Tendinopathy | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Tendinopathy with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Supraspinatus tendinopathy is one of the main pathologies that cause functional alterations in the glenohumeral joint. It reduces the quality of life of the population suffering from this injury. This pathology is the most frequent cause of pain in this joint. Symptoms are aggravated by repetitive work performed at or above shoulder height and sports that involve movements above the head.
Single-blind randomised clinical trial. The participants in this study will be patients selected from the ValleSur physiotherapy clinic in Ávila from January to May 2026. These patients will be diagnosed beforehand by an orthopaedic surgeon through a complete series of orthopaedic and complementary diagnostic tests. Following the clinical examination conducted by the principal investigator to verify the presence of tendinopathy in the supraspinatus and identify the selection criteria in the selected participants. Ultrasound imaging will be used to select the area to be treated. A single-blind clinical trial with a randomised design will be conducted, in which the evaluator will be blinded to assess the short- and medium-term efficacy of treatment with ultrasound-guided electrolysis. The results will then be compared with another intervention already performed with laser therapy for the same pathology and at the same centre.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment with simple electrolysis for shoulder tendinopathy.
Device: Simple electrolysis percutaneous
Treatment with multifilar electrolysis for shoulder tendinopathy.
Device: Multifiliar Electrolysis percutaneus
Laser on supraspinatus tendon.
Device: Laser
Treatment with simple electrolysis for shoulder tendinopathy.
Treatment with multifilar electrolysis for shoulder tendinopathy.
laser on supraspinatus tendon.
Intensity of pain
measured using the VAS scale, where 0 is the least possible pain and 10 is the greatest possible pain
Time frame: 1 week
Range of motion
Shoulder mobility in the joint ranges of flexion, extension, abduction, adduction, and external and internal rotation. Measurement in degrees using a goniometer
Time frame: 1 week
Patient quality of life
DASH questionnaire The score ranges from 0, which is equivalent to having no disability, to a maximum of 100, which is equivalent to having a very severe functional limitation.
Time frame: 1 week
Plan to share: Undecided
Ran from Jan 2026 to primary completion in Jul 2026, 6 months.
Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 6 months is below that.
Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jan 2026, on Oct 22, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Pontificia de Salamanca